CellFE develops a microfluidics-based device that delivers gene-editing molecules to enhance cell health and yield during the manufacturing of cell therapies. This technology addresses the challenges of long production times and high costs, enabling scalable and efficient processes from research to commercial applications.
Funding
$37.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Manufacturing cell therapies faces challenges related to long production times, high costs, scalability limitations, and maintaining cell health during gene editing. Traditional methods often struggle to efficiently deliver gene-editing molecules while preserving cell viability and functionality, hindering the widespread accessibility of these potentially life-saving treatments.
Solution
CellFE offers the Ryva™ Mechanoporation System, a microfluidics-based platform designed to enhance cell therapy manufacturing. The system utilizes a gentle mechanoporation process to deliver a wide range of gene-engineering payloads into cells, including large DNA vectors, with high precision and minimal cellular stress. This approach results in high cell viability, superior cell recovery, and efficient gene editing across various cell types, including T cells, HSCs, and iPSCs. The Ryva™ system streamlines workflows, reduces the need for specialized reagents, and enables seamless scaling from research to clinical and commercial applications, ultimately reducing manufacturing costs and improving access to cell therapies.
Target Audience
CellFE's primary customers are cell therapy researchers, developers, and manufacturers seeking to improve the efficiency, scalability, and cost-effectiveness of their cell therapy manufacturing processes.
Features
- Benchtop instrument with a small footprint, designed for use inside a biological safety cabinet
- Ryva™ Processing Units (PUPs) containing eight single-use processing units, allowing independent processing of samples
- Rapid processing time of less than 10 milliseconds per sample
- Intuitive software user interface for easy protocol creation and editing
- Flexible system capable of processing any or all eight samples in one run
- Compatibility with a wide range of gene-engineering payload types and sizes
- cGMP-compatible workflows for clinical-grade cell therapies
- Barcode reader and NFC tag for run history analysis
- Optimizer PUPs available for optimizing operating parameters for specific workflows